Key Highlights

● Third-quarter Revenue rose 39% to $24.4 billion, driven by tirzepatide.

● Full-year revenue guidance was raised to $91 billion to $92 billion.

● A brokerage raised its price target to $1,497 from $1,397.

● Health care sector gains are helping offset weakness in technology stocks.

Eli Lilly (NYSE:LLY) is extending its post-earnings rally. The drugmaker was indicated up 2.78% at $1,411.94 as of 8:23 a.m. ET, according to a premarket table, after jumping about 6.4% on Thursday to a record high, according to market data.

The catalyst was Lilly's third-quarter report. Revenue rose 39% to $24.4 billion, driven by its tirzepatide franchise, sold as Mounjaro for diabetes and Zepbound for obesity, and the company raised its full-year revenue guidance to $91 billion to $92 billion, according to market coverage. Earnings per share also beat expectations, according to premarket context.

One brokerage reiterated its Buy rating and raised its price target to $1,497 from $1,397, according to market reports. "Eli Lilly continues to dominate the obesity market category," the brokerage note said, as quoted in that report.

That dominance is the core of the bull case. Obesity drugs have become one of the largest growth markets in the history of the pharmaceutical industry, and Lilly's scale in Manufacturing and sales has allowed it to capture a large share of new prescriptions. Detailed product-level figures for Mounjaro and Zepbound in the quarter were not available in the sources reviewed.

A sector on a roll, and a crowded race

Lilly's results lifted the entire health care sector. The Health Care Select Sector SPDR, XLV, rose 2.43% on Thursday, according to market data, reaching a record high, and was up 1.23% premarket on Friday. Health care is among the sectors set for solid gains in October, according to market reports.

The rotation is partly about what investors are selling. With Nasdaq-100 futures down about 2.6% around 8 a.m. ET, according to market data, on worries about AI-related cash burn at Amazon (NASDAQ:AMZN) and Alphabet (NASDAQ:GOOGL), large drugmakers with strong growth and profits are attracting capital. Lilly is one of the largest companies in the S&P 500 by market value, so its gains help offset some of the drag from technology.

Other drugmakers are also climbing. AstraZeneca was up 4.87% and AbbVie (NYSE:ABBV) 3.20% premarket, according to market data, while Regeneron (NASDAQ:REGN) was up 6.87%, according to the premarket table. AbbVie raised its 2026 adjusted EPS guidance to $13.95 to $13.99.

Lilly is not alone in obesity. Novo Nordisk (NYSE:NVO), the maker of Wegovy and Ozempic, is its chief rival, and numerous companies are developing next-generation treatments, including oral pills and longer-acting injections. No new competitive data were reported this morning in the sources reviewed.

Risks and what to watch

At these levels, Lilly carries high expectations. Any sign of slowing prescription growth, pricing pressure or Supply constraints could hit the stock hard. Policy risk is significant: pharmaceutical tariffs under Section 232 can reach 100%, with negotiated deal rates of 15%, according to a government-affairs Tariff tracker. Drug pricing is also a political issue ahead of the Nov. 3 midterms, where prediction markets favor Democrats to win the House.

Competition could intensify as rivals bring new products to market, potentially eroding Lilly's share or pricing power. Valuation is another consideration: after Thursday's surge, the stock sits near all-time highs, which leaves less room for error if the next quarter fails to match the pace of the third. Big single-day gains can also attract profit-taking.

Watch whether Lilly holds above Thursday's record after the 9:30 a.m. ET open and whether more analysts raise targets. Amgen (NASDAQ:AMGN), which has its own obesity program, reports next week, and any competitive read-through could move the group.